To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Adcetris for first-line classical Hodgkin's lymphoma

FDA approved an sBLA from Seattle Genetics Inc. (NASDAQ:SGEN) for Adcetris brentuximab vedotin (SGN-35) in combination with chemotherapy to treat adults with previously untreated stage

Read the full 253 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE